Drugs / Quinfamide
Quinfamide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02385058 | Oct 2005 → Jan 2006 | amebiasis, helminthiasis | Janssen-Cilag Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quinfamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02385058 ↗ |
| Known as | Quinfamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107014 ↗ |
| Known as | WIN 40014 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107014 ↗ |
| Modality | Small molecule | — CHEMBL2107014 ↗ |
| Route | Oral | “Quinfamide 200 mg tablet orally once starting on Day 1 and 21.” NCT02385058 ↗ |